Tumori Foundation

Recent papers from Tumori Foundation

1. Stromal COL12A1 defines a pro-invasive extracellular matrix niche in appendiceal mucinous neoplasms and pseudomyxoma peritonei2026
2. Cytopathology and Prognostic Accuracy of 15-GEP/PRAMEJAMA Ophthalmology · 2026
3. Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registryClinical Cancer Research · 2026
4. Tumor Biology and Surgical Margin Patterns in Colorectal Liver Metastases: Association Between KRAS/BRAF Status and Type of Resection Margin—BRAF-KRAS LiverMet Collaborative GroupJournal of Laparoendoscopic & Advanced Surgical Techniques · 2026
5. Association of the Flemish Triage Risk Screening Tool with postoperative outcomes in older adults after colorectal cancer surgery: retrospective cohort studyBJS Open · 2026
6. Pattern and quality of care for rare head and neck cancers treated in expert centres: the experience of the registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)ESMO Open · 2026
7. Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgeryFuture Oncology · 2026
8. Preoperative prediction model of lymphovascular space invasion in endometrial cancer using ultrasound indicators and foundation model-based features: a multicenter studyScientific Reports · 2026
9. Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real‐world studyCancer · 2026
10. Right Ventricular Metastasis of Renal Cell Carcinoma and Late–onset Ici–induced Myocarditis: A Complex Cardio–oncology ScenarioEuropean Heart Journal Supplements · 2026
11. TFAP2B and FOXC1 are associated with biologically and clinically distinct differentiation states in triple-negative breast cancerScientific Reports · 2026
12. Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-ImmunotherapyCancers · 2026
13. 66 Relationship Between Health-related Quality of Life and Efficacy in the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in Previously Treated Advanced Clear Cell Renal Cell CarcinomaThe Oncologist · 2026
14. 34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 StudyThe Oncologist · 2026
15. Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitorsEuropean Journal of Cancer · 2026
16. Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open‐label, phase 2 trialCancer · 2026
17. From fragmentation to focus: building collaborative networks for rare cancer research – the Italian TYME network as a model for care and innovation?Expert Review of Anticancer Therapy · 2026
18. The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell EngagersJournal of Clinical Medicine · 2026
19. Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World SettingInternational Journal of Cancer · 2026
20. Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trialClinical Cancer Research · 2026